Chemical formula: C₂₅H₃₀N₆O₂ Molecular mass: 446.555 g/mol PubChem compound: 67462786
Erdafitinib is indicated for:
Population group: only adults (18 years old or older)
Erdafitinib as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Erdafitinib is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
